Biotech News

Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

PLUS THERAPEUTICS, Inc. (PSTV)PLUS THERAPEUTICS, Inc.2026-05-19 11:30 ESTPartnership

Partnership to deliver a novel AI-native integrated CNS oncology platform Platform will unify and analyze Plus’ proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision neuro-oncology HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc.

Related news

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

URGNUroGen Pharma2026-08-20 11:00 EST

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

MGNXMacroGenics2026-08-11 20:05 EST

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

RVMDRevolution Medicines2026-08-10 10:01 EST

Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration

SNYSanofi2026-09-14 13:03 EST

Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines

REGNRegeneron Pharmaceuticals2026-10-01 05:00 EST

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

SNYSanofi2026-10-01 05:00 EST

Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

KURAKura Oncology2026-09-09 11:00 EST

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

IDYAIDEAYA Biosciences2026-08-19 10:00 EST

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

View all latest news

PLUS THERAPEUTICS, Inc.

PLUS Therapeutics is an oncology company focused on radiotherapeutics and targeted treatment delivery for cancer. Its story is built around the use of radiation-based approaches to address hard-to-treat tumors.

Recent company news

PSTVPLUS THERAPEUTICS, Inc.2026-06-04 11:30 EST

Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

PSTVPLUS THERAPEUTICS, Inc.2026-05-26 11:30 EST

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

PSTVPLUS THERAPEUTICS, Inc.2026-05-19 11:30 EST

Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

PSTVPLUS THERAPEUTICS, Inc.2026-05-15 20:05 EST

Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

PSTVPLUS THERAPEUTICS, Inc.2026-05-08 11:30 EST

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

Stock data

Close: 3.87 USD
Market cap: 37.65M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States